Roivant Sciences Ltd (ROIV)
Profitability ratios
Return on sales
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 91.48% | 89.03% | 88.77% | 90.32% | 87.53% | 83.34% | 75.58% | 67.47% | 62.34% | 67.19% | 85.70% | 80.82% | 83.78% | 85.32% | 80.56% | 91.26% | 91.36% | 81.74% |
| Operating profit margin | -1,340.30% | -1,027.40% | 3,447.71% | 3,127.64% | 3,842.24% | 3,916.52% | -498.73% | -1,363.71% | -1,758.44% | -2,570.75% | -2,131.04% | -2,849.52% | -2,442.07% | -2,655.94% | -3,845.14% | -3,708.46% | -4,500.52% | -6,128.62% |
| Pretax margin | -776.70% | -594.75% | 3,781.64% | 2,937.20% | 3,408.34% | 3,461.24% | -1,177.62% | -1,528.46% | -1,998.75% | -3,100.36% | -2,501.32% | -2,260.55% | -1,670.85% | -1,953.07% | -2,734.12% | -3,314.34% | -3,776.20% | -3,877.49% |
| Net profit margin | -225.71% | -119.54% | 3,827.41% | 2,991.75% | 3,484.85% | 3,624.13% | -951.76% | -1,264.07% | -1,722.15% | -3,044.57% | -2,470.55% | -2,194.17% | -1,567.33% | -1,772.23% | -2,490.16% | -2,965.13% | -3,400.86% | -3,464.79% |
Roivant Sciences Ltd's profitability ratios have shown fluctuations over the past few years. The Gross Profit Margin has ranged from a high of 91.48% in March 2025 to a low of 62.34% in March 2023. This ratio measures the company's ability to generate profit from its core business activities.
The Operating Profit Margin has displayed significant volatility, with negative margins in the earlier years turning positive in later years. The company experienced a notable improvement in profitability, with margins reaching as high as 3,916.52% in December 2023, indicating a strong operational performance.
The Pretax Margin also reflects fluctuations, with negative margins in earlier years transitioning to positive margins in the later periods. The company saw a significant turnaround in profitability, recording a high of 3,781.64% in September 2024, demonstrating efficient management of expenses and income before taxes.
The Net Profit Margin, which represents the bottom line profitability after accounting for all expenses, has shown similar trends as the other ratios. The company experienced losses in the early years but managed to achieve positive margins in later periods, reaching a high of 3,827.41% in September 2024.
Overall, while Roivant Sciences Ltd has experienced fluctuations in profitability ratios over the years, there is evidence of improved operational efficiencies and financial performance in the more recent periods. It will be important for the company to sustain this positive trajectory to ensure long-term financial viability.
Return on investment
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -18.78% | -17.30% | 69.82% | 76.21% | 66.39% | 66.01% | -24.91% | -50.16% | -45.09% | -50.33% | -48.49% | -56.84% | -52.23% | -58.07% | -52.81% | -45.25% | -41.35% | — |
| Return on assets (ROA) | -3.16% | -2.01% | 77.51% | 72.90% | 60.21% | 61.08% | -47.53% | -46.49% | -44.16% | -59.60% | -56.22% | -43.77% | -33.52% | -38.75% | -34.20% | -36.18% | -31.25% | — |
| Return on total capital | -8.71% | 90.56% | 78.55% | 78.94% | 69.69% | -18.38% | -117.60% | -118.52% | -90.35% | -119.39% | -92.57% | -106.79% | -66.22% | -72.34% | -80.41% | -64.47% | -59.57% | — |
| Return on equity (ROE) | -3.67% | -2.25% | 86.20% | 87.13% | 72.86% | 73.34% | -103.50% | -109.07% | -91.15% | -137.42% | -107.32% | -82.23% | -42.50% | -48.27% | -52.07% | -51.54% | -45.01% | — |
Roivant Sciences Ltd has experienced fluctuations in its profitability ratios over the past few years. The Operating Return on Assets (Operating ROA) shows a significant improvement from negative values in 2021 and 2022 to positive values in 2023 and 2024, indicating that the company has been able to generate profits from its operations relative to its assets.
Similarly, the Return on Assets (ROA) also displays an upward trend, with the company transitioning from negative returns to positive returns in 2023 and 2024. This suggests that Roivant Sciences Ltd has been more efficient in utilizing its assets to generate profits for its stakeholders.
On the other hand, the Return on Total Capital ratio demonstrates a volatile pattern, reflecting drastic negative returns in 2021 and 2022, followed by a significant improvement in 2024. This indicates that the company may have faced challenges in generating returns on the total capital invested initially, but has shown progress in recent years.
Lastly, the Return on Equity (ROE) ratio reveals a similar trend to the ROA ratios, with negative values in 2021 and 2022 transitioning to positive returns in 2023 and 2024. This suggests that Roivant Sciences Ltd has been able to provide satisfactory returns to its equity investors in the past two years.
Overall, the profitability ratios of Roivant Sciences Ltd demonstrate a mixed performance, with recent improvements indicating a positive outlook for the company's profitability and efficiency in generating returns for its stakeholders.